644 Shares in argenx SE (NASDAQ:ARGX) Acquired by Callan Family Office LLC

Callan Family Office LLC acquired a new stake in argenx SE (NASDAQ:ARGX - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 644 shares of the company's stock, valued at approximately $396,000.

A number of other large investors have also bought and sold shares of ARGX. Whipplewood Advisors LLC acquired a new position in shares of argenx during the fourth quarter worth about $37,000. Global Retirement Partners LLC boosted its position in argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after acquiring an additional 48 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after acquiring an additional 61 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of argenx in the fourth quarter valued at approximately $66,000. Finally, Nkcfo LLC acquired a new stake in shares of argenx in the fourth quarter valued at approximately $68,000. 60.32% of the stock is owned by institutional investors.

argenx Stock Down 1.7 %

ARGX stock traded down $10.24 during midday trading on Thursday, reaching $581.21. 347,169 shares of the company's stock traded hands, compared to its average volume of 284,224. The firm's fifty day moving average price is $639.30 and its 200-day moving average price is $595.27. argenx SE has a 52 week low of $349.86 and a 52 week high of $678.21. The company has a market cap of $35.31 billion, a price-to-earnings ratio of -660.47 and a beta of 0.59.

Remove Ads

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. Analysts forecast that argenx SE will post 3.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ARGX shares. Wells Fargo & Company raised their target price on shares of argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. Robert W. Baird raised their price objective on argenx from $650.00 to $680.00 and gave the company a "neutral" rating in a report on Tuesday, March 4th. HC Wainwright upped their target price on argenx from $717.00 to $720.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Truist Financial restated a "buy" rating and issued a $700.00 price target (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Finally, Oppenheimer upped their price objective on argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. Three analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $687.00.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.